Zobrazeno 1 - 10
of 151
pro vyhledávání: ''
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Autor:
Ismail, R. K., Schramel, F. M.N.H., van Dartel, M., Hilarius, D. L., de Boer, A., Wouters, M. W.J.M., Smit, H. J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Lung Cancer, 149, 68. Elsevier Ireland Ltd.
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Objectives This study describes the initiation of the Dutch Lung Cancer Audit for Lung Oncology (DLCA-L) and reports the first results of three years of clinical auditing. Methods The initiation, dataset, and data quality of the DLCA-L are described.
Autor:
Ron Pritzkuleit, Bernd Holleczek, Gundula Behrens, Lina Jansen, Lars Schwettmann, Michael Gerken, Isabelle Finke, Hermann Brenner
Publikováno v:
Lung Cancer 142, 1-8 (2020)
Publons
Publons
Objectives Studies from several countries reported socioeconomic inequalities in lung cancer survival. Hypothesized reasons are differences in cancer care or tumor characteristics. We investigated associations of small-area deprivation and lung cance
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Aline Bobato Lara Gongora, Bruna Migliavacca Zucchetti, Olavo Feher, Maurício Fernando Silva Almeida Ribeiro, Andrea K. Shimada, Artur Katz, Felipe de Galiza Barbosa, Leandro Jonata Carvalho Oliveira, Karina Perez Sacardo, Joao Victor Machado Alessi
Publikováno v:
Lung Cancer. 139:9-12
Objectives to report outcomes of four cases of chemo-refractory RET-rearranged non-small cell lung carcinomas (NSCLCs) treated with alectinib in a single center. Materials and methods we retrospectively assessed and reported the activity and tolerabi
Autor:
Dong Wook Shin, Jong Ho Cho, Su Min Jeong, Dong Woog Yoon, Sang Hyun Park, Jeong Hoon Yang, Kyungdo Han
Publikováno v:
Lung Cancer. 136:115-121
Objectives With advances in lung cancer treatments, the number of lung cancer survivors has increased. As cardiovascular diseases (CVD) are some of the major causes of non-cancer deaths, CVD management is an integral part of cancer survivorship care.
Publikováno v:
Lung cancer, 134, 34-41. Elsevier
Objectives Increased emphasis on molecular diagnostics can lead to increased variation in time to treatment (TTT) for patients with stage III and IV non-small cell lung cancer. This article presents the variation in TTT for advanced NSCLC patients ob
Autor:
Santiago Viteri, Santiago Ramón y Cajal, José Ignacio Toscas, Irene Moya-Horno, José Antonio Maestre-Alcácer, Rafael Rosell, Laura Romero-Vielva
Publikováno v:
Lung Cancer. 133:117-122
Introduction Despite all treatment advances, lung cancer is still the main cause of death worldwide. Treatment for resectable stage IIIA remains controversial including definitive chemoradiotherapy and induction treatment followed by surgery. After d
Autor:
Johan Vansteenkiste, Amanda Tufman, M. Guckenberger, Dirk De Ruysscher, Miklos Pless, N. Andratschke, Maarten Lambrecht, Alex Martinez-Marti, Antonio Irigoyen, M. Kassapian, A.-C. Piguet, H. Roschitzki-Voser, Enriqueta Felip, Manuela Rabaglio-Poretti, Rolf A. Stahel, Urania Dafni, Claus Belka, H. Vees, Solange Peters, E. Nadal, A. Becker
Publikováno v:
Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, A C, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, R A, Vansteenkiste, J & De Ruysscher, D 2019, ' Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial ', Lung Cancer, vol. 133, pp. 83-87 . https://doi.org/10.1016/j.lungcan.2019.05.001
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material
Autor:
Shannon M. Nugent, Kelly C. Vranas, Donald R. Sullivan, Christopher G. Slatore, Sara E. Golden, Nathan F. Dieckmann, Karen Eden
Publikováno v:
Lung Cancer
Introduction With advances in treatments among patients with lung cancer, it is increasingly important to understand patients’ values and preferences to facilitate shared decision making. Methods Prospective, multicenter study of patients with trea